Shohei Eto
University of Tokushima
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shohei Eto.
Asian Journal of Endoscopic Surgery | 2014
Chie Takasu; Mitsuo Shimada; Hirohiko Sato; Tomohiko Miyatani; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Mami Kanamoto; Nobuhiro Kurita; Shohei Eto; Tohru Utsunomiya
Recently, consensus on the optimal strategy for resectable synchronous colorectal liver metastases (LM) seems to have shifted toward simultaneous resection. However, there are still relatively few reports about simultaneous laparoscopic resection. The aim of this study is to evaluate the outcomes of patients who underwent simultaneous laparoscopic resection.
Oncology Reports | 2015
Toshihiro Nakao; Takashi Iwata; Masanori Hotchi; Kozo Yoshikawa; Jun Higashijima; Masaaki Nishi; Chie Takasu; Shohei Eto; Hiroki Teraoku; Mitsuo Shimada
Preoperative chemoradiotherapy (CRT) has become the standard treatment for patients with locally advanced rectal cancer. However, no specific biomarker has been identified to predict a response to preoperative CRT. The aim of the present study was to assess the gene expression patterns of patients with advanced rectal cancer to predict their responses to preoperative CRT. Fifty-nine rectal cancer patients were subjected to preoperative CRT. Patients were randomly assigned to receive CRT with tegafur/gimeracil/oteracil (S-1 group, n=30) or tegafur-uracil (UFT group, n=29). Gene expression changes were studied with cDNA and miRNA microarray. The association between gene expression and response to CRT was evaluated. cDNA microarray showed that 184 genes were significantly differentially expressed between the responders and the non‑responders in the S-1 group. Comparatively, 193 genes were significantly differentially expressed in the responders in the UFT group. TBX18 upregulation was common to both groups whereas BTNL8, LOC375010, ADH1B, HRASLS2, LOC284232, GCNT3 and ALDH1A2 were significantly differentially lower in both groups when compared with the non-responders. Using miRNA microarray, we found that 7 and 16 genes were significantly differentially expressed between the responders and non-responders in the S-1 and UFT groups, respectively. miR-223 was significantly higher in the responders in the S-1 group and tended to be higher in the responders in the UFT group. The present study identified several genes likely to be useful for establishing individualized therapies for patients with rectal cancer.
The Journal of Medical Investigation | 2018
Masaaki Nishi; Mistuo Shimada; Kozo Yoshikawa; Jun Higashijima; Takuya Tokunaga; Hideya Kashihara; Chie Takasu; Daichi Ishikawa; Yuma Wada; Shohei Eto
BACKGROUND Surgical indication for hepatic resection is controversial in gastric cancer liver metastasis (GLM). The aim of this study is to clarify the effect of hepatic resection for GLM. METHODOLOGY Ten patients who underwent hepatic resection for GLM between 2001 and 2013 were enrolled in this study. Six patients underwent synchronous hepatic resection and gastrectomy, and the remaining four patients underwent metachronous hepatic resection. Six patients had solitary liver metastasis, and 4 patients had multiple liver metastasis. The median follow-up period was 12.4 months (the range being 0.5 months to 50 months). RESULT The actual 1- year and 3-year overall survival rates for the patients who underwent hepatic resection are 88.9% and 17.8%, respectively. The median survival time was 21.5 months. And the 1-year recurrence free survival time was 20.0%. The median recurrence free survival rate was 4.7 months. Regarding post-operative recurrence, synchronous hepatic resection tended to be a recurrence factor (p=0.08). CONCLUSION Hepatic resection for GLM has an acceptable outcome. Metachronous hepatic resection tends to have a better outcome than synchronous hepatic resection for the treatment of GLM. J. Med. Invest. 65:27-31, February, 2018.
International Surgery | 2017
Shohei Eto; Kozo Yoshikawa; Takashi Iwata; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Masaaki Nishi; Hideya Kashihara; Chie Takasu; Mitsuo Shimada; Toru Kono
Introduction: Crohns disease (CD) is a chronic inflammatory bowel disease, which affect the entire gastrointestinal tract. Treatment basis for CD is medication to control the inflammation and reli...
Journal of Clinical Oncology | 2015
Jun Higashijima; Mitsuo Shimada; Takashi Iwata; Kozo Yoshikawa; Toshihiro Nakao; Masaaki Nishi; Chie Takasu; Shohei Eto
620 Background: Oxaliplatin(Ox) based regimen is widely used in colorectal cancer patients.One of the major adverse effects of Ox is a neuropathy. There is no useful biomarker predicting such adverse effect. The aim of this study is to evaluate platinum concentration as a biomarker predicting the adverse effect. Methods: Ten patients who underwent curative colectomy were included in this study. Final stage of all patients was UICC stage III. All patients underwent adjuvant chemotherapy by CapeOX regimen for eight cycles (or six months). Blood samples were collected after fourth cycle and last cycle. Ox concentration was measured in red blood cells (RBC) and serum, and evaluated the kinetics of platinum (PL) in blood. In addition, we investigated relationship between Ox concentration and adverse effects. Results: 1) Kinetics of PL concentration: PL concentration in RBC tended to be correlated with the difference of RBC numbers between pre- and post-chemotherapy (R2=0.358, p=0.068). The PL concentration in ...
Journal of Clinical Oncology | 2014
Motoya Chikakiyo; Hirohiko Sato; Nobuhiro Kurita; Takashi Iwata; Kozo Yoshikawa; Hideya Kashihara; Chie Mikami; Noriko Matsumoto; Shohei Eto; Mitsuo Shimada; Masanori Hotchi; Hiroshi Okitsu; Yasuhide Sonaka; Sadahiro Yoshida
563 Background: Recent pharmacogenetic studies have revealed a significant association between uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) polymorphisms *28 and *6 and toxicities such as severe diarrhea and neutropenia under treatment with irinotecan. Moreover, the latter of these two polymorphisms is specifically detected in East Asian populations. We performed a prospective study to determine the optimal dose of this drug depending on which polymorphism is present in order to maximize the effectiveness of therapy while avoiding side effects. Methods: 59 patients from 11 institutions were enrolled in this study. Patients were assigned to one of the following three groups: wild type (*1/*1), heterozygous (*28/*1, *6/*1), or homozygous (*28/*28, *6/*6*, *28/*6*). The double heterozygous state (*28/*6) was included within the homozygous group. Second-line FOLFIRI was administered, with the dose of irinotecan at 150 mg/m2, in the wild type and heterozygous groups and at 100 mg/m2 in the homozygo...
Gastric Cancer | 2016
Shohei Eto; Kozo Yoshikawa; Masaaki Nishi; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Chie Takasu; Takashi Iwata; Mitsuo Shimada
Anticancer Research | 2014
Noriko Matsumoto; Kozo Yoshikawa; Mitsuo Shimada; Nobuhiro Kurita; Hirohiko Sato; Takashi Iwata; Jun Higashijima; Motoya Chikakiyo; Masaaki Nishi; Hideya Kashihara; Chie Takasu; Shohei Eto; Akira Takahashi; Masatake Akutagawa; Takahiro Emoto
Anticancer Research | 2015
Shohei Eto; Kozo Yoshikawa; Mitsuo Shimada; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Masaaki Nishi; Chie Takasu; Hirohiko Sato; Nobuhiro Kurita
Journal of Clinical Oncology | 2015
Shohei Eto; Takashi Iwata; Kozo Yoshikawa; Jun Higashijima; Toshihiro Nakao; Masaaki Nishi; Chie Takasu; Mitsuo Shimada